Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Horwitz EM, et al. Among authors: porter a. J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14. J Clin Oncol. 2008. PMID: 18413638 Clinical Trial.
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. Hanks GE, et al. Among authors: porter a. J Clin Oncol. 2003 Nov 1;21(21):3972-8. doi: 10.1200/JCO.2003.11.023. J Clin Oncol. 2003. PMID: 14581419 Clinical Trial.
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM; Radiation Therapy Oncology Group Protocol 92-02. Valicenti RK, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. doi: 10.1016/j.ijrobp.2006.06.017. Epub 2006 Sep 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979837
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.
Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. Roach M 3rd, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1314-22. doi: 10.1016/j.ijrobp.2009.09.073. Epub 2010 Apr 8. Int J Radiat Oncol Biol Phys. 2010. PMID: 20378270 Free PMC article. Clinical Trial.
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.
Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. Rodrigues G, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):445-52. doi: 10.1016/j.ijrobp.2010.02.034. Epub 2010 Aug 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20615632 Free PMC article. Clinical Trial.
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Pilepich MV, et al. Among authors: porter a. J Clin Oncol. 1997 Mar;15(3):1013-21. doi: 10.1200/JCO.1997.15.3.1013. J Clin Oncol. 1997. PMID: 9060541 Clinical Trial.
Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV. Lawton CA, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):931-9. doi: 10.1016/s0360-3016(97)00288-5. Int J Radiat Oncol Biol Phys. 1997. PMID: 9276357 Clinical Trial.
Diagnostic and prognostic markers for human prostate cancer.
Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV. Gao X, et al. Among authors: porter at. Prostate. 1997 Jun 1;31(4):264-81. doi: 10.1002/(sici)1097-0045(19970601)31:4<264::aid-pros8>3.0.co;2-k. Prostate. 1997. PMID: 9180937 Review.
Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio.
Forman JD, Duclos M, Sharma R, Chuba P, Hart K, Yudelev M, Devi S, Court W, Shamsa F, Littrup P, Grignon D, Porter A, Maughan R. Forman JD, et al. Among authors: porter a. Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):259-66. doi: 10.1016/0360-3016(96)00020-x. Int J Radiat Oncol Biol Phys. 1996. PMID: 8635931 Clinical Trial.
1,820 results